Synergistic Effects of Combining Hsp90 and PI3K Inhibitors with Everolimus in Pancreatic Neuroendocrine Tumors Abstract #1869

Introduction: The development of the first molecular targeted therapies for neuroendocrine tumors (NET) was a milestone in the treatment of patient. Nevertheless, these therapies eventually fail and patients become resistant to the treatment. One way of escaping this dilemma might be the combination of targeted drugs to prevent resistance development.
Aim(s): The aim of the study was to assess the potency and synergistic effects of different targeted therapies in NET.
Materials and methods: We studied the effect of mono- and combination therapies of the PI3K inhibitor BYL719, Hsp90 inhibitor AUY922 and mTOR inhibitor Everolimus in the human pancreatic NET cell lines BON, QGP-1 and NT-3. Signal pathway activation was analyzed by western blot.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr Joerg Schrader

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1553 A Novel In Vitro Model of a Highly Proliferative Pancreatic Neuroendocrine Neoplasia
Introduction: Transformation of well-differentiated neuroendocrine tumors into highly proliferative neuroendocrine neoplasms is a rare, but clinical relevant phenomenon. So far, it is unclear whether these tumors should be treated in analogy to neuroendocrine tumors or as bona fide neuroendocrine carcinoma.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Joerg Schrader
Authors: Behrang Y, Benten D, Erbes J, Eggers C, ...
Keywords: cell line
#898 Evaluation of Tumor Response to Targeted Therapies in Precision-Cut Slices of Human Pancreatic Neuroendocrine Tumors
Introduction: Patients with PNET might benefit from new therapeutic approaches acting on the mTOR signaling pathway. Culture of precision-cut slices could allow testing these molecules in human tumors, allowing personalized treatments.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Margot Bucau
#1775 Potential Therapeutic Targets for Gastric Poorly Differentiated Neuroendocrine Carcinoma
Introduction: Gastric poorly differentiated neuroendocrine carcinoma (G-PDNEC) is rare and aggressive. Patients often present with distant metastases at initial diagnosis.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: PROF. Yuan Ji
Authors: Ji Y, Xie Y, Chen K, Zeng H, ...
#437 mTOR Expression in Primary Pancreatic Neuroendocrine Tumors and their Metastases
Introduction: The mammalian target of rapamycin (mTOR), an important regulator of cell proliferation and invasion, is activated in pancreatic neuroendocrine tumors (PNETs). Information on detailed expression of mTOR in locally advanced or metastatic PNET is poorly described.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof Vera Delektorskaya
Authors: Kozlov N, Pavlovskaya A, ...
#2004 OPALINE Study: Observational Study in a Real-World Setting of the Systemic Treatment of Progressive Unresectable or Well-Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)
Introduction: OPALINE Study focuses on patients with pNET. 2 targeted therapies (TT) offer new options to treat these patients: mTORi (everolimus) and a multi-targeted inhibitor (sunitinib).
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: Alexandre Santos